InvestorsHub Logo
Followers 1
Posts 118
Boards Moderated 0
Alias Born 10/24/2012

Re: rusty8350 post# 1859

Wednesday, 08/16/2017 9:56:23 AM

Wednesday, August 16, 2017 9:56:23 AM

Post# of 2296
Revenues during the second quarter of 2017 were $1.6 million compared to $1.2 million for the same period in 2016. Revenues for each period consisted of contract and grant revenue under the Company's U.S. government awards for the development of Tetraphase compounds for the treatment of diseases caused by bacterial biothreat pathogens and for certain infections caused by life-threatening multidrug-resistant bacteria